Using engineered nanoparticles to improve cancer treatment by modulating the immune system
Engineered Nanoformulation for Immune-modulation in Cancer
['FUNDING_R01'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-10907737
This study is looking at how tiny particles can help boost your immune system to fight cancer better by blocking certain proteins that stop your immune cells from working, which could lead to new and more effective treatments for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-10907737 on ClinicalTrials.gov |
What this research studies
This research investigates how engineered nanoformulations can enhance the immune response against cancer by targeting immune checkpoint molecules that inhibit T-cell activity. The approach involves using lipid-based nanoparticles to deliver siRNA that silences specific proteins in cancer cells, potentially leading to improved tumor eradication. By understanding the interaction between cancer drugs and immune checkpoints, the research aims to develop new therapies that can overcome treatment failures. Patients may benefit from more effective cancer treatments that harness their immune system's capabilities.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that express immune checkpoint proteins and who may not have responded well to conventional therapies.
Not a fit: Patients with early-stage cancers that are easily treatable with standard therapies may not receive significant benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve patient outcomes and survival rates.
How similar studies have performed: Previous studies have shown promising results with similar approaches using immune checkpoint inhibitors and targeted therapies in cancer treatment.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAMESH, RAJAGOPAL — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: RAMESH, RAJAGOPAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents